Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionubiquitin protein ligase activity

WWP1 WWP2 BSPRY

4.96e-0437293GO:0061630
GeneOntologyMolecularFunctionubiquitin-like protein ligase activity

WWP1 WWP2 BSPRY

6.04e-0439893GO:0061659
GeneOntologyMolecularFunctionubiquitin-protein transferase activity

WWP1 WWP2 BSPRY

9.97e-0447393GO:0004842
GeneOntologyMolecularFunctionubiquitin-like protein transferase activity

WWP1 WWP2 BSPRY

1.25e-0351293GO:0019787
GeneOntologyMolecularFunctionaminoacyltransferase activity

WWP1 WWP2 BSPRY

1.40e-0353293GO:0016755
GeneOntologyMolecularFunctionacyltransferase activity

WWP1 WWP2 BSPRY

4.10e-0377593GO:0016746
GeneOntologyMolecularFunctionRNA polymerase II-specific DNA-binding transcription factor binding

STRN WWP2

1.42e-0241792GO:0061629
DomainE3_ub_ligase_SMURF1

WWP1 WWP2

2.06e-07292IPR024928
DomainHECT

WWP1 WWP2

7.20e-052792PF00632
DomainHECT_dom

WWP1 WWP2

7.20e-052792IPR000569
DomainHECTc

WWP1 WWP2

7.20e-052792SM00119
DomainHECT

WWP1 WWP2

7.20e-052792PS50237
DomainWW

WWP1 WWP2

2.21e-044792PF00397
DomainWW

WWP1 WWP2

2.30e-044892SM00456
DomainWW_DOMAIN_1

WWP1 WWP2

2.60e-045192PS01159
DomainWW_DOMAIN_2

WWP1 WWP2

2.60e-045192PS50020
DomainWW_dom

WWP1 WWP2

2.70e-045292IPR001202
DomainC2

WWP1 WWP2

1.70e-0313192PF00168
DomainC2

WWP1 WWP2

1.86e-0313792SM00239
DomainC2

WWP1 WWP2

2.00e-0314292PS50004
Domain-

WWP1 WWP2

2.16e-03148922.60.40.150
DomainC2_dom

WWP1 WWP2

2.65e-0316492IPR000008
Pubmed

WWP1 knockout in mice exacerbates obesity-related phenotypes in white adipose tissue but improves whole-body glucose metabolism.

WWP1 WWP2

5.95e-0829231965758
Pubmed

Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases.

WWP1 WWP2

1.79e-0739212450395
Pubmed

Disinhibition of the HECT E3 ubiquitin ligase WWP2 by polymerized Dishevelled.

WWP1 WWP2

3.57e-0749226701932
Pubmed

Anterograde transport of surfactant protein C proprotein to distal processing compartments requires PPDY-mediated association with Nedd4 ubiquitin ligases.

WWP1 WWP2

5.95e-0759219366705
Pubmed

A HECT domain ubiquitin ligase closely related to the mammalian protein WWP1 is essential for Caenorhabditis elegans embryogenesis.

WWP1 WWP2

5.95e-0759210903445
Pubmed

A Tunable Brake for HECT Ubiquitin Ligases.

WWP1 WWP2

5.95e-0759228475870
Pubmed

Polarity Acquisition in Cortical Neurons Is Driven by Synergistic Action of Sox9-Regulated Wwp1 and Wwp2 E3 Ubiquitin Ligases and Intronic miR-140.

WWP1 WWP2

5.95e-0759230392800
Pubmed

Inhibition of HECT E3 ligases as potential therapy for COVID-19.

WWP1 WWP2

5.95e-0759233762578
Pubmed

Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins.

WWP1 WWP2

8.92e-076929647693
Pubmed

Transmembrane adaptor protein WBP1L regulates CXCR4 signalling and murine haematopoiesis.

WWP1 WWP2

1.25e-0679231845480
Pubmed

A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover.

WWP1 WWP2

1.67e-0689219307600
Pubmed

Patched-1 proapoptotic activity is downregulated by modification of K1413 by the E3 ubiquitin-protein ligase Itchy homolog.

WWP1 WWP2

2.68e-06109225092867
Pubmed

USP11 augments TGFβ signalling by deubiquitylating ALK5.

WWP1 WWP2

3.27e-06119222773947
Pubmed

Damage-induced ubiquitylation of human RNA polymerase II by the ubiquitin ligase Nedd4, but not Cockayne syndrome proteins or BRCA1.

WWP1 WWP2

3.27e-06119217996703
Pubmed

Multiple interactions between the ESCRT machinery and arrestin-related proteins: implications for PPXY-dependent budding.

WWP1 WWP2

3.27e-06119221191027
Pubmed

Dysregulated Inflammatory Signaling upon Charcot-Marie-Tooth Type 1C Mutation of SIMPLE Protein.

WWP1 WWP2

3.27e-06119225963657
Pubmed

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling.

WWP1 WWP2

5.41e-06149231015455
Pubmed

Assembly and structure of Lys33-linked polyubiquitin reveals distinct conformations.

WWP1 WWP2

7.13e-06169225723849
Pubmed

Ubiquitin-assisted phase separation of dishevelled-2 promotes Wnt signalling.

STRN WWP1 WWP2

8.01e-061619336398662
Pubmed

RNF11 sequestration of the E3 ligase SMURF2 on membranes antagonizes SMAD7 down-regulation of transforming growth factor β signaling.

WWP1 WWP2

8.08e-06179228292929
Pubmed

Identification of novel human WW domain-containing proteins by cloning of ligand targets.

WWP1 WWP2

9.09e-0618929169421
Pubmed

SCFFBXL¹⁵ regulates BMP signalling by directing the degradation of HECT-type ubiquitin ligase Smurf1.

WWP1 WWP2

1.02e-05199221572392
Pubmed

WWP2 ubiquitylates RNA polymerase II for DNA-PK-dependent transcription arrest and repair at DNA breaks.

WWP1 WWP2 SETX UBAP2L

1.14e-056159431048545
Pubmed

PTPN14 is required for the density-dependent control of YAP1.

WWP1 WWP2

1.25e-05219222948661
Pubmed

Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer.

WWP1 WWP2

1.25e-05219237005481
Pubmed

ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.

WWP1 WWP2

1.25e-05219229416926
Pubmed

USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling.

WWP1 WWP2

1.37e-05229224850914
Pubmed

System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes.

WWP1 WWP2

1.93e-05269226949039
Pubmed

WWP2 is an E3 ubiquitin ligase for PTEN.

WWP1 WWP2

2.41e-05299221532586
Pubmed

Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.

WWP1 WWP2

5.10e-05429227578003
Pubmed

Ring Finger Protein 11 acts on ligand-activated EGFR via the direct interaction with the UIM region of ANKRD13 protein family.

WWP1 WWP2

8.78e-05559231985874
Pubmed

Optimizing Nervous System-Specific Gene Targeting with Cre Driver Lines: Prevalence of Germline Recombination and Influencing Factors.

WWP1 WWP2

1.05e-04609232027825
Pubmed

USP9X Deubiquitylates DVL2 to Regulate WNT Pathway Specification.

WWP1 WWP2

1.12e-04629231340145
Pubmed

K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains.

WWP1 WWP2

1.23e-04659229378950
Pubmed

Identification of proximal SUMO-dependent interactors using SUMO-ID.

STRN SETX UBAP2L

1.64e-044449334795231
Pubmed

A cascading activity-based probe sequentially targets E1-E2-E3 ubiquitin enzymes.

WWP1 WWP2

2.25e-04889227182664
Pubmed

A probability-based approach for high-throughput protein phosphorylation analysis and site localization.

WWP2 SETX UBAP2L

2.37e-045039316964243
InteractionABRAXAS2 interactions

WWP1 WWP2 BSPRY

9.74e-0610093int:ABRAXAS2
InteractionFAM120A interactions

WWP1 FASTKD2 WWP2 UBAP2L

1.04e-0534994int:FAM120A
InteractionWBP1L interactions

WWP1 WWP2

1.17e-051292int:WBP1L
InteractionTMEM255A interactions

WWP1 WWP2

2.40e-051792int:TMEM255A
InteractionTFPT interactions

EAF2 STRN SETX

3.98e-0516093int:TFPT
InteractionCPSF6 interactions

STRN WWP1 WWP2 UBAP2L

5.21e-0552694int:CPSF6
InteractionCLCN5 interactions

WWP1 WWP2

5.29e-052592int:CLCN5
InteractionPOLR2G interactions

WWP1 WWP2 SETX

5.56e-0517993int:POLR2G
InteractionDVL2 interactions

EAF2 STRN WWP1 WWP2

6.51e-0555794int:DVL2
InteractionFBXL15 interactions

WWP1 WWP2

7.15e-052992int:FBXL15
InteractionIL6R interactions

WWP1 WWP2

7.66e-053092int:IL6R
InteractionANKRD17 interactions

WWP2 BSPRY UBAP2L

1.11e-0422693int:ANKRD17
InteractionIL2RG interactions

WWP1 WWP2

1.30e-043992int:IL2RG
InteractionWBP1 interactions

WWP1 WWP2

1.51e-044292int:WBP1
InteractionHSPB1 interactions

STRN WWP1 WWP2 PNISR

1.65e-0470894int:HSPB1
InteractionH4C11 interactions

WWP1 WWP2

1.74e-044592int:H4C11
InteractionARRDC2 interactions

WWP1 WWP2

2.51e-045492int:ARRDC2
InteractionNDFIP2 interactions

WWP1 WWP2

2.70e-045692int:NDFIP2
InteractionSMAD6 interactions

WWP1 WWP2

2.70e-045692int:SMAD6
InteractionLDLRAD4 interactions

WWP1 WWP2

2.99e-045992int:LDLRAD4
InteractionFBXL18 interactions

WWP1 WWP2

3.10e-046092int:FBXL18
InteractionWWP2 interactions

WWP1 WWP2 SETX UBAP2L

3.19e-0484094int:WWP2
InteractionSCNN1A interactions

WWP1 WWP2

3.52e-046492int:SCNN1A
InteractionCPSF7 interactions

WWP1 WWP2 UBAP2L

3.64e-0433893int:CPSF7
InteractionLAPTM5 interactions

WWP1 WWP2

3.86e-046792int:LAPTM5
InteractionARRDC1 interactions

WWP1 WWP2

3.98e-046892int:ARRDC1
InteractionITCH interactions

WWP1 WWP2 UBAP2L

4.24e-0435693int:ITCH
InteractionEWSR1 interactions

WWP1 WWP2 PNISR UBAP2L

4.26e-0490694int:EWSR1
InteractionPTEN interactions

WWP1 WWP2 SETX UBAP2L

4.69e-0492994int:PTEN
InteractionLITAF interactions

WWP1 WWP2

5.10e-047792int:LITAF
InteractionWBP2 interactions

WWP1 WWP2

5.78e-048292int:WBP2
InteractionARRDC4 interactions

WWP1 WWP2

5.92e-048392int:ARRDC4
InteractionENTREP1 interactions

WWP1 WWP2

6.35e-048692int:ENTREP1
InteractionNUFIP2 interactions

WWP1 WWP2 UBAP2L

6.73e-0441793int:NUFIP2
InteractionPALS1 interactions

WWP1 WWP2

6.80e-048992int:PALS1
InteractionRABEP2 interactions

STRN WWP2

7.43e-049392int:RABEP2
InteractionAMOTL1 interactions

WWP1 WWP2

7.75e-049592int:AMOTL1
InteractionMIR19A interactions

WWP1 WWP2

8.58e-0410092int:MIR19A
InteractionTMEM51 interactions

WWP1 WWP2

8.92e-0410292int:TMEM51
InteractionSPART interactions

WWP1 WWP2

9.10e-0410392int:SPART
InteractionDDX1 interactions

STRN WWP2 UBAP2L

9.13e-0446393int:DDX1
InteractionMIR19B1 interactions

WWP1 WWP2

9.27e-0410492int:MIR19B1
InteractionRPS7 interactions

WWP1 WWP2 UBAP2L

9.30e-0446693int:RPS7
InteractionBABAM1 interactions

STRN WWP2

9.45e-0410592int:BABAM1
InteractionNDFIP1 interactions

WWP1 WWP2

9.45e-0410592int:NDFIP1
InteractionRPL30 interactions

WWP1 WWP2 UBAP2L

9.77e-0447493int:RPL30
InteractionGPN3 interactions

WWP1 WWP2

9.81e-0410792int:GPN3
InteractionLSM14B interactions

WWP2 UBAP2L

1.02e-0310992int:LSM14B
InteractionNHSL3 interactions

STRN WWP2

1.09e-0311392int:NHSL3
InteractionTFAP2A interactions

WWP1 WWP2

1.11e-0311492int:TFAP2A
InteractionRECQL5 interactions

WWP1 WWP2

1.11e-0311492int:RECQL5
InteractionSRSF3 interactions

WWP1 FASTKD2 WWP2

1.29e-0352293int:SRSF3
InteractionGPN1 interactions

WWP1 WWP2

1.29e-0312392int:GPN1
InteractionCAPNS1 interactions

WWP1 WWP2

1.31e-0312492int:CAPNS1
InteractionPATJ interactions

WWP1 WWP2

1.34e-0312592int:PATJ
InteractionCCDC85C interactions

WWP1 WWP2

1.34e-0312592int:CCDC85C
InteractionRUNX2 interactions

WWP1 WWP2

1.36e-0312692int:RUNX2
InteractionSMAD7 interactions

WWP1 WWP2

1.38e-0312792int:SMAD7
InteractionPOLR2A interactions

WWP1 WWP2 SETX

1.39e-0353693int:POLR2A
InteractionEEF1E1 interactions

STRN WWP2

1.42e-0312992int:EEF1E1
InteractionPOLR2M interactions

WWP1 WWP2

1.44e-0313092int:POLR2M
InteractionSQSTM1 interactions

FASTKD2 WWP2 SETX UBAP2L

1.47e-03125794int:SQSTM1
InteractionBRCC3 interactions

WWP1 WWP2

1.49e-0313292int:BRCC3
InteractionDAG1 interactions

WWP1 WWP2

1.53e-0313492int:DAG1
InteractionPOLR2I interactions

WWP1 WWP2

1.55e-0313592int:POLR2I
InteractionLYPD3 interactions

STRN FASTKD2

1.69e-0314192int:LYPD3
InteractionFAM168A interactions

WWP1 WWP2

1.72e-0314292int:FAM168A
InteractionURI1 interactions

WWP1 WWP2

1.74e-0314392int:URI1
InteractionSF3B5 interactions

STRN WWP2

1.74e-0314392int:SF3B5
InteractionPOLR2F interactions

WWP2 SETX

1.77e-0314492int:POLR2F
InteractionCDKN1B interactions

WWP1 WWP2

1.77e-0314492int:CDKN1B
InteractionDVL1 interactions

WWP1 WWP2

1.94e-0315192int:DVL1
InteractionAMOTL2 interactions

WWP1 WWP2

1.94e-0315192int:AMOTL2
InteractionPOLR2J interactions

WWP1 WWP2

1.97e-0315292int:POLR2J
InteractionPOLR2D interactions

WWP1 WWP2

1.99e-0315392int:POLR2D
InteractionMTPAP interactions

FASTKD2 WWP2

2.02e-0315492int:MTPAP
InteractionCNTNAP2 interactions

STRN UBAP2L

2.12e-0315892int:CNTNAP2
InteractionRPAP2 interactions

WWP1 WWP2

2.15e-0315992int:RPAP2
InteractionSETX interactions

WWP2 SETX

2.15e-0315992int:SETX
InteractionRPL19 interactions

WWP1 WWP2 UBAP2L

2.30e-0363893int:RPL19
InteractionFBL interactions

WWP1 WWP2 UBAP2L

2.31e-0363993int:FBL
InteractionRASA1 interactions

WWP1 WWP2

2.37e-0316792int:RASA1
InteractionTP73 interactions

WWP1 WWP2

2.42e-0316992int:TP73
InteractionRNF11 interactions

WWP1 WWP2

2.42e-0316992int:RNF11
InteractionRPL11 interactions

WWP1 FASTKD2 WWP2

2.45e-0365293int:RPL11
InteractionUBAP2 interactions

WWP2 UBAP2L

2.45e-0317092int:UBAP2
InteractionGYPA interactions

FASTKD2 SETX

2.56e-0317492int:GYPA
InteractionDIDO1 interactions

WWP1 WWP2

2.62e-0317692int:DIDO1
InteractionPTPN14 interactions

WWP1 WWP2

2.65e-0317792int:PTPN14
InteractionPCBP1 interactions

WWP1 WWP2 UBAP2L

2.66e-0367193int:PCBP1
GeneFamilyC2 and WW domain containing

WWP1 WWP2

2.20e-07442838
CoexpressionNAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP

EAF2 FASTKD2 BSPRY PNISR SETX UBAP2L

7.30e-07121596M41122
CoexpressionNAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN

FASTKD2 WWP2 PNISR UBAP2L

5.10e-0568094M41089
CoexpressionGOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN

STRN WWP1 WWP2 PNISR

3.30e-04110294M2369
CoexpressionNAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN

FASTKD2 PNISR UBAP2L

3.47e-0443293M41149
CoexpressionGOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN

STRN WWP1 WWP2 PNISR

3.56e-04112494MM1070
CoexpressionGARY_CD5_TARGETS_DN

WWP1 FASTKD2 UBAP2L

3.66e-0444093M13893
CoexpressionGAUTAM_EYE_IRIS_CILIARY_BODY_SCHWANN_CELLS

WWP1 PNISR

4.22e-049192M43622
CoexpressionMILI_PSEUDOPODIA_HAPTOTAXIS_UP

STRN WWP1 FASTKD2

6.07e-0452393M12707
CoexpressionMILI_PSEUDOPODIA_HAPTOTAXIS_UP

STRN WWP1 FASTKD2

6.45e-0453493MM1054
CoexpressionDESCARTES_FETAL_MUSCLE_MYELOID_CELLS

EAF2 WWP1

8.59e-0413092M40259
CoexpressionLAKE_ADULT_KIDNEY_C20_COLLECTING_DUCT_INTERCALATED_CELLS_TYPE_A_CORTEX

WWP1 PNISR

1.17e-0315292M39239
CoexpressionHAMAI_APOPTOSIS_VIA_TRAIL_UP

WWP1 PNISR SETX

1.17e-0365693M18979
CoexpressionGSE10500_ARTHRITIC_SYNOVIAL_FLUID_VS_HEALTHY_MACROPHAGE_UP

STRN BSPRY

1.22e-0315592M358
CoexpressionGSE27896_HDAC6_KO_VS_WT_TREG_UP

STRN SETX

1.56e-0317692M8248
CoexpressionGSE2935_UV_INACTIVATED_VS_LIVE_SENDAI_VIRUS_INF_MACROPHAGE_DN

WWP1 BSPRY

1.64e-0318092M6317
CoexpressionGSE7218_IGM_VS_IGG_SIGNAL_THGOUGH_ANTIGEN_BCELL_UP

FASTKD2 SETX

1.76e-0318792M6807
CoexpressionGSE13485_DAY1_VS_DAY21_YF17D_VACCINE_PBMC_UP

PNISR UBAP2L

1.84e-0319192M3298
CoexpressionGSE15659_TREG_VS_TCONV_UP

WWP1 UBAP2L

1.88e-0319392M3534
CoexpressionMTOR_UP.N4.V1_UP

EAF2 BSPRY

1.93e-0319692M2757
CoexpressionGSE16266_LPS_VS_HEATSHOCK_AND_LPS_STIM_MEF_DN

EAF2 WWP1

1.97e-0319892M7217
CoexpressionGSE6875_TCONV_VS_TREG_UP

EAF2 STRN

1.97e-0319892M6799
CoexpressionGSE27786_BCELL_VS_CD8_TCELL_DN

BSPRY SETX

1.99e-0319992M4802
CoexpressionGSE39556_CD8A_DC_VS_NK_CELL_MOUSE_3H_POST_POLYIC_INJ_DN

PNISR SETX

1.99e-0319992M9418
CoexpressionGSE40666_WT_VS_STAT4_KO_CD8_TCELL_DN

EAF2 WWP1

1.99e-0319992M9223
CoexpressionGSE22886_DAY0_VS_DAY7_MONOCYTE_IN_CULTURE_UP

PNISR SETX

1.99e-0319992M4460
CoexpressionGSE32986_UNSTIM_VS_GMCSF_AND_CURDLAN_LOWDOSE_STIM_DC_UP

EAF2 BSPRY

1.99e-0319992M8619
CoexpressionGSE360_CTRL_VS_B_MALAYI_HIGH_DOSE_DC_DN

STRN WWP2

1.99e-0319992M5151
CoexpressionGSE11961_MARGINAL_ZONE_BCELL_VS_GERMINAL_CENTER_BCELL_DAY7_UP

FASTKD2 PNISR

1.99e-0319992M9320
CoexpressionGSE36009_WT_VS_NLRP10_KO_DC_LPS_STIM_DN

FASTKD2 PNISR

1.99e-0319992M8770
CoexpressionGSE22886_NAIVE_CD4_TCELL_VS_12H_ACT_TH1_UP

WWP1 SETX

1.99e-0319992M4521
CoexpressionGSE22886_NAIVE_CD4_TCELL_VS_12H_ACT_TH2_UP

WWP1 PNISR

1.99e-0319992M4526
CoexpressionGSE10240_IL17_VS_IL17_AND_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP

WWP2 UBAP2L

1.99e-0319992M313
CoexpressionGSE21927_C26GM_VS_4T1_TUMOR_MONOCYTE_BALBC_DN

WWP1 PNISR

1.99e-0319992M7607
CoexpressionGSE33162_HDAC3_KO_VS_HDAC3_KO_4H_LPS_STIM_MACROPHAGE_UP

STRN WWP1

2.01e-0320092M9041
CoexpressionGSE39556_UNTREATED_VS_3H_POLYIC_INJ_MOUSE_CD8A_DC_DN

WWP1 PNISR

2.01e-0320092M9408
CoexpressionGSE5589_IL6_KO_VS_IL10_KO_LPS_STIM_MACROPHAGE_45MIN_UP

WWP2 UBAP2L

2.01e-0320092M6653
CoexpressionGSE5503_PLN_DC_VS_SPLEEN_DC_ACTIVATED_ALLOGENIC_TCELL_DN

FASTKD2 SETX

2.01e-0320092M297
CoexpressionGSE32986_UNSTIM_VS_CURDLAN_HIGHDOSE_STIM_DC_UP

EAF2 BSPRY

2.01e-0320092M8614
CoexpressionGSE369_SOCS3_KO_VS_WT_LIVER_DN

PNISR SETX

2.01e-0320092M5963
CoexpressionGSE24292_WT_VS_PPARG_KO_MACROPHAGE_DN

WWP1 PNISR

2.01e-0320092M8054
CoexpressionGSE17186_NAIVE_VS_CD21LOW_TRANSITIONAL_BCELL_DN

WWP1 SETX

2.01e-0320092M7197
CoexpressionGSE23502_BM_VS_COLON_TUMOR_HDC_KO_MYELOID_DERIVED_SUPPRESSOR_CELL_DN

STRN SETX

2.01e-0320092M8081
CoexpressionGSE3720_UNSTIM_VS_LPS_STIM_VD1_GAMMADELTA_TCELL_UP

WWP1 SETX

2.01e-0320092M6357
CoexpressionGSE22886_NAIVE_CD4_TCELL_VS_48H_ACT_TH1_UP

PNISR SETX

2.01e-0320092M4524
CoexpressionAtlasFacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_2500_k-means-cluster#1

WWP1 FASTKD2 PNISR SETX

2.71e-0546994Facebase_RNAseq_e8.5_Floor Plate_2500_K1
CoexpressionAtlasDevelopingGonad_e14.5_ ovary_emap-6699_top-relative-expression-ranked_1000

EAF2 STRN PNISR UBAP2L

1.93e-0477694gudmap_developingGonad_e14.5_ ovary_1000
CoexpressionAtlasDevelopingLowerUrinaryTract_e13.5_bladder epithelial cells_emap-30875_top-relative-expression-ranked_1000

EAF2 STRN WWP2 BSPRY

1.96e-0478094gudmap_developingLowerUrinaryTract_e13.5_bladder epithelial cells_1000
ToppCellSubstantia_nigra-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Igfbp2_(Igfbp2)--|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EAF2 PNISR

1.17e-0482926875a10abf1221b3dfd954c319b5e8e12fac1ff2
ToppCellSubstantia_nigra-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Igfbp2_(Igfbp2)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EAF2 PNISR

1.17e-04829289aff8676f98e062d0e69b38c7184e51aa1a915e
ToppCellSubstantia_nigra-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Igfbp2_(Igfbp2)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EAF2 PNISR

1.17e-048292259bb4ae0373d8352cb1c3bff08f66b89a298440
ToppCell5'-GW_trimst-1.5-SmallIntestine-Epithelial-epithelial_progenitor_cell-Distal_progenitor|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

EAF2 BSPRY

4.34e-0415892ab707bfe782c667b252b488ad1d7efd49cf0a899
ToppCelldroplet-Limb_Muscle-nan-21m-Lymphocytic-B_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

EAF2 BSPRY

5.14e-041729262734d231290ca725276dc62faa2ac87bd1b37b8
ToppCellPBMC-Convalescent-Lymphocyte-B-B_cell-B_memory-B_memory-0|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

EAF2 BSPRY

5.56e-0417992fce1ba53815145f6248d4e90aedca3dad84e33e4
ToppCelldroplet-Limb_Muscle-nan-21m-Lymphocytic-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

EAF2 BSPRY

5.69e-0418192923b369b1404103f124fcbffa866de26f9d68d33
ToppCelldroplet-Limb_Muscle-nan-21m-Lymphocytic|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

EAF2 BSPRY

5.69e-04181927fd96238673c9596562c43e7c5ddbab7d0e6c0c6
ToppCellfacs-Heart-LV-18m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

EAF2 SETX

5.75e-04182926dff753d65ba45db81f3cc0c9f59e1779d490955
ToppCellnormal_Lung-B_lymphocytes-Follicular_B_cells|normal_Lung / Location, Cell class and cell subclass

EAF2 PNISR

5.75e-041829213c39228f76495deca6b948483bbde426b3e8c5b
ToppCellCV-Severe-4|CV / Virus stimulation, Condition and Cluster

EAF2 UBAP2L

5.75e-0418292c19bbc43d97c426aec37414f46f667a19b62a257
ToppCellCV-Moderate-4|CV / Virus stimulation, Condition and Cluster

EAF2 BSPRY

5.88e-041849290f5b447064743246b09a6c47bf561efafa15e1f
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)

WWP1 PNISR

5.94e-0418592fcd95bc074e982fc7b8fd48d2e80038b9ea35ebb
ToppCellCV-Moderate-4|Moderate / Virus stimulation, Condition and Cluster

EAF2 BSPRY

5.94e-04185924a3ce0c603c2ffe11f0f00775b6af4f6d9a6070a
ToppCellTCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9

WWP1 SETX

6.00e-041869203db813598b67b1e08f759758a1c2023396921fa
ToppCellCD8+_Memory_T_cell-CV-4|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster

EAF2 BSPRY

6.07e-04187929c2fc2f259fa7d3a65fb99c295ac378e03d9aa6c
ToppCellMS-CD8-CD4_Treg|MS / Condition, Cell_class and T cell subcluster

STRN FASTKD2

6.13e-04188922f0e2c7d79ee2d69a5d908c0247dc950c056c30a
ToppCellmetastatic_Lymph_Node-B_lymphocytes-Undetermined|metastatic_Lymph_Node / Location, Cell class and cell subclass

EAF2 PNISR

6.13e-04188920ddc5dbe2fd905fee20c33d9845629e259faacd9
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-A|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

STRN SETX

6.26e-041909263018acb7ad80415e861643162abdc2e55968ee4
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)

WWP1 FASTKD2

6.33e-0419192696921a4f160b6b55698652488ed781e855e5e51
ToppCellcontrol-Lymphoid-CTL|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

PNISR SETX

6.46e-041939289d407a88b5956559a589425b89b3eb8dc78e1dd
ToppCellmetastatic_Lymph_Node-B_lymphocytes-Follicular_B_cells|metastatic_Lymph_Node / Location, Cell class and cell subclass

EAF2 PNISR

6.53e-041949205453f8c4d7f742b41d647d574a28555bf78ae39
ToppCellnormal_Pleural_Fluid-B_lymphocytes-Follicular_B_cells|normal_Pleural_Fluid / Location, Cell class and cell subclass

EAF2 PNISR

6.53e-0419492678da250aa881ff29482bc464affca7a5f360dc5
ToppCellnormal_Pleural_Fluid-B_lymphocytes|normal_Pleural_Fluid / Location, Cell class and cell subclass

EAF2 PNISR

6.53e-0419492a3192698248561462d8d3bdaeabdff563a07019f
ToppCellmetastatic_Lymph_Node-B_lymphocytes|metastatic_Lymph_Node / Location, Cell class and cell subclass

EAF2 PNISR

6.59e-0419592820250198c787223eb4e073db11a983851ddcdd2
ToppCellsevere_COVID-19-B_naive|severe_COVID-19 / disease group, cell group and cell class (v2)

EAF2 PNISR

6.66e-04196921a2b7c3f00098e9b4c0659b8714a0e4cf9f86f27
ToppCellmild-CD4+_T_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

WWP1 PNISR

6.87e-04199923e4baaf4ee23f257d821194468102c00a8ad2f21
ToppCellMild/Remission-B_naive-9|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

EAF2 PNISR

6.87e-0419992e9af3c6a05f435ac8d7066f54feb653012b51ffb
ToppCell(04)_Interm._basal>secr.-(2)_GFP_FOXI1|(04)_Interm._basal>secr. / shred by cell type by condition

WWP1 SETX

6.87e-041999253ca3861f9e00dab3f3fbefb0837857ee39ab084
ToppCell(09)_Interm._secr.>cil.-(2)_GFP_FOXI1|(09)_Interm._secr.>cil. / shred by cell type by condition

WWP1 SETX

6.87e-0419992fc680f85ebd3bab4c72876a19a461b0afb5f51ce
ToppCellmild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

PNISR SETX

6.93e-042009212f1685ce8f218433068e090c9d839cd5a1910bf
ToppCellSepsis-Int-URO-Lymphocyte-B|Int-URO / Disease, condition lineage and cell class

EAF2 PNISR

6.93e-04200929596e5f1a6cc7dfafc8d68ebd53ff32c41b06256
ToppCellInfluenza-Influenza_Severe-Lymphocyte-B|Influenza_Severe / Disease, condition lineage and cell class

EAF2 PNISR

6.93e-0420092bf238a0a074d6c5cba8cb73d3b715ee701a612b6
ToppCellSepsis-Int-URO-Lymphocyte-B-B_naive|Int-URO / Disease, condition lineage and cell class

EAF2 PNISR

6.93e-0420092d2bf9792503fbe84f1dcac8c8ca02b504a07ab45
Druglomustine; Up 200; 100uM; PC3; HT_HG-U133A

EAF2 WWP2 SETX

3.81e-05178937094_UP
Drug0316684-0000 [391209-55-5]; Up 200; 10uM; PC3; HT_HG-U133A

EAF2 WWP2 SETX

4.85e-05193937098_UP
DrugPerphenazine [58-39-9]; Down 200; 10uM; PC3; HG-U133A

WWP1 PNISR UBAP2L

5.00e-05195931956_DN
DrugICI182,780; Up 200; 1uM; PC3; HT_HG-U133A

EAF2 WWP2 PNISR

5.00e-05195936918_UP
DrugNiacin [59-67-6]; Down 200; 32.4uM; MCF7; HT_HG-U133A

EAF2 PNISR UBAP2L

5.16e-05197935301_DN
DrugHexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; PC3; HT_HG-U133A

EAF2 PNISR SETX

5.16e-05197936620_DN
DrugFluocinonide [356-12-7]; Down 200; 8uM; MCF7; HT_HG-U133A

EAF2 STRN PNISR

5.24e-05198933414_DN
DrugPyrithyldione [77-04-3]; Down 200; 24uM; MCF7; HT_HG-U133A

EAF2 STRN UBAP2L

5.24e-05198936801_DN
DrugDiltiazem hydrochloride [33286-22-5]; Down 200; 8.8uM; HL60; HG-U133A

WWP1 FASTKD2 PNISR

5.31e-05199932032_DN
DrugMinocycline hydrochloride [13614-98-7]; Down 200; 8uM; MCF7; HT_HG-U133A

EAF2 STRN UBAP2L

5.31e-05199935496_DN
DrugAmidopyrine [58-15-1]; Down 200; 17.2uM; HL60; HG-U133A

WWP2 PNISR SETX

5.39e-05200931376_DN
Drugpenton

WWP1 WWP2

1.19e-044292CID000006550
DrugBioquinon

EAF2 SETX

1.15e-0313192CID000001156
Druggeldanamycin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

EAF2 SETX

1.84e-03166921066_UP
DrugAntigens, Polyomavirus Transforming

STRN SETX UBAP2L

1.85e-0366893ctd:D000952
Drugthapsigargin; Up 200; 0.1uM; MCF7; HT_HG-U133A

EAF2 SETX

1.88e-03168927100_UP
DrugProscillaridin A [466-06-8]; Down 200; 7.6uM; MCF7; HT_HG-U133A

EAF2 SETX

2.00e-03173927340_DN
Druggeldanamycin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

EAF2 SETX

2.02e-0317492864_UP
DrugSAHA; Down 200; 10uM; PC3; HT_HG-U133A

WWP2 PNISR

2.04e-03175921220_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

PNISR UBAP2L

2.11e-03178927245_DN
Druggeldanamycin; Up 200; 1uM; PC3; HT_HG-U133A

FASTKD2 SETX

2.13e-03179924452_UP
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A_EA

STRN PNISR

2.18e-03181921077_UP
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A

WWP1 SETX

2.20e-03182923887_DN
DrugStrophanthidin [66-28-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A

EAF2 SETX

2.20e-03182926087_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HG-U133A

FASTKD2 PNISR

2.20e-03182921951_DN
DrugHarmine hydrochloride [343-27-1]; Down 200; 16uM; MCF7; HT_HG-U133A

EAF2 FASTKD2

2.23e-03183922750_DN
DrugZuclopenthixol hydrochloride [633-59-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A

EAF2 SETX

2.23e-03183924843_UP
DrugPuromycin dihydrochloride [58-58-2]; Down 200; 7.4uM; MCF7; HT_HG-U133A

WWP1 UBAP2L

2.23e-03183923310_DN
Drugscriptaid; Up 200; 10uM; MCF7; HT_HG-U133A

EAF2 STRN

2.25e-03184926901_UP
Drugtyrphostin AG-825; Down 200; 25.2uM; MCF7; HT_HG-U133A_EA

WWP1 SETX

2.28e-03185921114_DN
DrugPyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; MCF7; HT_HG-U133A

EAF2 UBAP2L

2.30e-03186923518_DN
DrugICI 182,780; Down 200; 0.01uM; MCF7; HT_HG-U133A

STRN PNISR

2.33e-03187925598_DN
Drugprochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HT_HG-U133A

STRN FASTKD2

2.33e-03187926975_UP
DrugAG-1478; Down 200; 31.6uM; MCF7; HT_HG-U133A_EA

PNISR UBAP2L

2.33e-03187921141_DN
Drugtrichostatin A; Down 200; 0.1uM; PC3; HG-U133A

PNISR UBAP2L

2.33e-0318792448_DN
Drugikarugamycin; Up 200; 2uM; MCF7; HT_HG-U133A_EA

STRN PNISR

2.35e-0318892974_UP
Druglomustine; Down 200; 100uM; PC3; HT_HG-U133A

FASTKD2 PNISR

2.35e-03188927050_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

STRN UBAP2L

2.37e-03189921005_DN
Drug17-DMAG; Down 200; 0.1uM; MCF7; HT_HG-U133A

STRN UBAP2L

2.42e-03191925210_DN
DrugNitrofural [59-87-0]; Down 200; 20.2uM; PC3; HT_HG-U133A

STRN UBAP2L

2.42e-03191926721_DN
DrugBupivacaine hydrochloride [18010-40-7]; Down 200; 12.4uM; MCF7; HT_HG-U133A

EAF2 STRN

2.42e-03191927435_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

STRN UBAP2L

2.45e-03192925222_DN
DrugAzacyclonol [115-46-8]; Down 200; 15uM; PC3; HG-U133A

WWP1 UBAP2L

2.45e-03192921937_DN
Drug5279552; Up 200; 22uM; MCF7; HT_HG-U133A_EA

STRN UBAP2L

2.45e-0319292960_UP
DrugHesperidin [520-26-3]; Down 200; 6.6uM; PC3; HT_HG-U133A

STRN PNISR

2.45e-03192926714_DN
Drug3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; MCF7; HT_HG-U133A

STRN FASTKD2

2.45e-03192923382_DN
DrugCotinine (-) [486-56-6]; Down 200; 22.6uM; PC3; HG-U133A

WWP1 PNISR

2.45e-03192921929_DN
DrugMethotrexate [59-05-2]; Down 200; 8.8uM; PC3; HG-U133A

WWP1 PNISR

2.47e-03193921957_DN
DrugAG-012559 [369370-06-9]; Up 200; 10uM; PC3; HT_HG-U133A

WWP2 PNISR

2.47e-03193926920_UP
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

EAF2 STRN

2.47e-03193921022_DN
DrugCanrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; MCF7; HT_HG-U133A

EAF2 STRN

2.47e-03193926783_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

STRN UBAP2L

2.47e-03193925215_DN
DrugGallamine triethiodide [65-29-2]; Down 200; 4.4uM; MCF7; HT_HG-U133A

WWP2 UBAP2L

2.47e-03193926215_DN
Drug5114445; Down 200; 10uM; MCF7; HT_HG-U133A_EA

EAF2 UBAP2L

2.47e-0319392901_DN
DrugAstemizole [68844-77-9]; Down 200; 8.8uM; PC3; HT_HG-U133A

STRN PNISR

2.47e-03193922049_DN
DrugAntimycin A [1397-94-0]; Down 200; 7.2uM; PC3; HT_HG-U133A

SETX UBAP2L

2.47e-03193922098_DN
DrugChlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; PC3; HG-U133A

WWP1 PNISR

2.47e-03193921958_DN
Druggeldanamycin; Down 200; 1uM; MCF7; HT_HG-U133A

WWP2 PNISR

2.47e-03193926946_DN
DrugLY 294002; Up 200; 10uM; HL60; HT_HG-U133A

STRN FASTKD2

2.50e-03194926195_UP
DrugTiabendazole [148-79-8]; Down 200; 19.8uM; MCF7; HT_HG-U133A

STRN PNISR

2.50e-03194922840_DN
DrugDexamethasone acetate [1177-87-3]; Down 200; 9.2uM; HL60; HG-U133A

WWP1 WWP2

2.50e-03194921396_DN
DrugAztreonam [78110-38-0]; Down 200; 9.2uM; PC3; HT_HG-U133A

SETX UBAP2L

2.50e-03194922118_DN
DrugRetinoic acid [302-79-4]; Down 200; 13.4uM; MCF7; HT_HG-U133A

PNISR UBAP2L

2.50e-03194926243_DN
DrugImidurea [39236-46-9]; Down 200; 10.4uM; MCF7; HT_HG-U133A

EAF2 STRN

2.50e-03194923522_DN
DrugH-89, Dihydrochloride; Up 200; 0.5uM; PC3; HT_HG-U133A

EAF2 PNISR

2.50e-03194926921_UP
Drugtrifluoperazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A

STRN FASTKD2

2.50e-03194925221_DN
DrugTerbutaline hemisulfate [23031-32-5]; Down 200; 7.2uM; HL60; HG-U133A

WWP2 PNISR

2.50e-03194921585_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

EAF2 UBAP2L

2.50e-03194926995_DN
DrugIodixanol [92339-11-2]; Up 200; 2.6uM; MCF7; HT_HG-U133A

EAF2 PNISR

2.53e-03195924848_UP
Drugionomycin calcium salt; Up 200; 2uM; MCF7; HT_HG-U133A_EA

EAF2 SETX

2.53e-0319592871_UP
DrugFenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A

STRN SETX

2.53e-03195923721_DN
DrugAcenocoumarol [152-72-7]; Down 200; 11.4uM; MCF7; HT_HG-U133A

EAF2 FASTKD2

2.53e-03195922240_DN
DrugSulfadimethoxine [122-11-2]; Down 200; 12.8uM; PC3; HT_HG-U133A

STRN SETX

2.53e-03195927400_DN
DrugRimexolone [49697-38-3]; Down 200; 10.8uM; PC3; HT_HG-U133A

EAF2 UBAP2L

2.53e-03195925092_DN
DrugHemicholinium bromide [312-45-8]; Down 200; 7uM; MCF7; HT_HG-U133A

EAF2 PNISR

2.53e-03195925339_DN
DrugIproniazide phosphate [305-33-9]; Down 200; 14.4uM; PC3; HT_HG-U133A

STRN UBAP2L

2.53e-03195922125_DN
DrugMetaraminol bitartrate [33402-03-8]; Down 200; 8.6uM; PC3; HT_HG-U133A

EAF2 STRN

2.53e-03195927368_DN
DrugAmprolium hydrochloride [137-88-2]; Down 200; 12.6uM; HL60; HG-U133A

PNISR UBAP2L

2.53e-03195921979_DN
DrugEtofenamate [30544-47-9]; Down 200; 10.8uM; MCF7; HT_HG-U133A

EAF2 PNISR

2.53e-03195927327_DN
DrugBW-B 70C; Down 200; 31.6uM; MCF7; HT_HG-U133A_EA

PNISR UBAP2L

2.53e-03195921132_DN
DrugAtractyloside potassium salt [102130-43-8]; Up 200; 5uM; PC3; HT_HG-U133A

WWP2 PNISR

2.53e-03195927393_UP
Drugradicicol, diheterospora chlamydosporia; Down 200; 0.1uM; HL60; HT_HG-U133A

STRN WWP1

2.53e-03195921160_DN
DrugRisperidone [106266-06-2]; Down 200; 9.8uM; MCF7; HT_HG-U133A

FASTKD2 UBAP2L

2.53e-03195923508_DN
DrugKawain [500-64-1]; Down 200; 17.4uM; PC3; HT_HG-U133A

BSPRY SETX

2.55e-03196927369_DN
DrugNicergoline; Down 200; 8.2uM; PC3; HT_HG-U133A

EAF2 PNISR

2.55e-03196922058_DN
DrugPapaverine hydrochloride [61-25-6]; Down 200; 10.6uM; MCF7; HT_HG-U133A

PNISR UBAP2L

2.55e-03196926245_DN
DrugAtractyloside potassium salt [102130-43-8]; Up 200; 5uM; MCF7; HT_HG-U133A

STRN BSPRY

2.55e-03196923435_UP
DrugOrlistat; Up 200; 10uM; MCF7; HT_HG-U133A

EAF2 STRN

2.55e-03196926905_UP
DrugPhthalylsulfathiazole [85-73-4]; Down 200; 10uM; MCF7; HT_HG-U133A

EAF2 STRN

2.55e-03196925249_DN
DrugSulfaguanidine [57-67-0]; Up 200; 18.6uM; PC3; HG-U133A

PNISR UBAP2L

2.55e-03196921913_UP
DrugBacitracin [1405-87-4]; Down 200; 2.8uM; MCF7; HT_HG-U133A

EAF2 STRN

2.55e-03196927448_DN
DrugSyrosingopine [84-36-6]; Down 200; 6uM; PC3; HT_HG-U133A

STRN UBAP2L

2.55e-03196925733_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

FASTKD2 UBAP2L

2.55e-03196926940_DN
DrugSulfaphenazole [526-08-9]; Down 200; 12.8uM; PC3; HT_HG-U133A

WWP2 BSPRY

2.55e-03196921794_DN
DrugTranexamic acid [1197-18-8]; Down 200; 25.4uM; MCF7; HT_HG-U133A

EAF2 STRN

2.55e-03196926238_DN
DrugTrimetazidine dihydrochloride [13171-25-0]; Down 200; 11.8uM; PC3; HT_HG-U133A

EAF2 STRN

2.55e-03196925060_DN
Drugrapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

EAF2 UBAP2L

2.55e-0319692921_DN
DrugNorfloxacin [70458-96-7]; Down 200; 12.6uM; PC3; HT_HG-U133A

STRN UBAP2L

2.55e-03196922090_DN
Diseaseamino acid measurement

FASTKD2 WWP2 SETX

9.15e-0467893EFO_0005134

Protein segments in the cluster

PeptideGeneStartEntry
FQNGLHAWMVNVQNS

BSPRY

281

Q5W0U4
QQQQQMWNSARTPNL

EAF2

126

Q96CJ1
QPQQNSQLMWKQGRQ

STRN

146

O43815
SNWNILNNFHNRMQS

FASTKD2

56

Q9NYY8
NQHWNQLIQDAQKRG

SETX

2431

Q7Z333
QWQSQRNQLQGAMQH

WWP2

371

O00308
RGNWEQPQNQNQTQH

UBAP2L

11

Q14157
QWPLNQQQWMQSFQH

PNISR

11

Q8TF01
QQQWMQSFQHQQDPS

PNISR

16

Q8TF01
EQWQSQRNQLQGAMQ

WWP1

421

Q9H0M0